Search
Mavorixafor
go.drugbank.com/drugs/DB05501ApprovedInvestigational[L50647] WHIM syndrome is caused by mutations in the _CXCR4_ gene, which leads to overactivation of CXCR4 signalling pathways.[A263652] Mavorixafor prevents the activation of CXCR4. … [L50642] It was first approved by the FDA on April 30, 2024, for the treatment of warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome, a genetic immunodeficiency disorder characterized
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 SubstratesMK-1496
go.drugbank.com/drugs/DB12763InvestigationalMK-1496 has been used in trials studying the treatment of Neoplasms and Malignant.
MK-5108
go.drugbank.com/drugs/DB12556InvestigationalMK-5108 has been used in trials studying the treatment of Cancer, Neoplasms, Tumors.
Modakafusp alfa
go.drugbank.com/drugs/DB16399InvestigationalMultiple Myeloma (MM)). … Modakafusp alfa is under investigation in clinical trial NCT03215030 (A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-573 in Participants With Refractory
Human papillomavirus type 16
go.drugbank.com/conditions/DBCOND0093637Synonyms: HPV-16, Human Papillomavirus 16MM-111
go.drugbank.com/drugs/DB17983InvestigationalMM-111 is a novel bispecific antibody fusion protein that co-targets the the epidermal growth factor family receptor tyrosine kinases, ERBB2 and ERBB3.
Lutein
go.drugbank.com/drugs/DB00137ApprovedNutraceuticalIn green plants, xanthophylls act to modulate light energy and serve as non-photochemical quenching agents to deal with triplet chlorophyll (an excited form of chlorophyll), which is overproduced at very … Lutein is an xanthophyll and one of 600 known naturally occurring carotenoids.
Ordesekimab
go.drugbank.com/drugs/DB16649InvestigationalOrdesekimab is under investigation in clinical trial NCT02633020 (Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease).
GC012F
go.drugbank.com/drugs/DB22406InvestigationalGC012F is under investigation in clinical trial NCT06419166 (An Exploratory Clinical Study of GC012F Injection for Refractory gMG).